The effects of anti-CXCL12/CXCR4 therapies have been most extensively studied in hematological malignancies, in which monoclonal CXCR4 targeting antibodies such as Ulocuplumab, have been tested with varying results. This evidence concerns the gene CXCR4 and hematologic disorder.